SRXH · Company research
SRX Global Inc (SRXH): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
22records availableConsumer
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| IBRX Stock Climbs Premarket Despite Investor Stake Cut — Retail Sees ‘Imminent’ Global Rollout Catalyst - Stocktwits | IBRX Stock Climbs Premarket Despite Investor Stake Cut — Retail Sees ‘Imminent’ Global Rollout Catalyst Stocktwits | View source ↗ | Stocktwits | Oct 13, 2026 | neutral | 0 | 0.6 |
| SRXH Stock Climbed 15% Today — What’s Driving The Rally? - Stocktwits | SRXH Stock Climbed 15% Today — What’s Driving The Rally? Stocktwits | View source ↗ | Stocktwits | Oct 12, 2026 | neutral | 0 | 0.6 |
| SRX Global Inc. (SRXH) stock price, news, quote and history - Yahoo Finance UK | SRX Global Inc. (SRXH) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 9, 2026 | neutral | 0 | 0.6 |
| SRX Global Inc. (SRXH) latest stock news and headlines - Yahoo Finance UK | SRX Global Inc. (SRXH) latest stock news and headlines Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 9, 2026 | neutral | 0 | 0.6 |
| SRX Global Inc. (SRXH) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore | SRX Global Inc. (SRXH) latest stock news and headlines – Yahoo Finance Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 9, 2026 | neutral | 0 | 0.6 |
| SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies | SRX Global Inc. announced a definitive agreement to acquire CERo Therapeutics Holdings, Inc., an innovative cellular immunotherapy company developing CER-1236 for hematologic malignancies. The acquisition will be structured through a wholly-owned SPV (CERO 1236) to avoid diluting existing SRX shareholders. The transaction is expected to accelerate CER-1236's clinical development and provide CERo with enhanced access to capital and operational resources. CERo has treated six patients in its Phase 1 CERTAIN-T trial with no dose-limiting toxicities observed at increased dose levels. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 1 | 1 |
| SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies | SRX Global Inc. announced a definitive agreement to acquire CERo Therapeutics Holdings, Inc., an innovative cellular immunotherapy company developing CER-1236 for hematologic malignancies. The acquisition will be structured through a wholly-owned SPV (CERO 1236) to avoid diluting existing SRX shareholders. The transaction is expected to accelerate CER-1236's clinical development and provide CERo with enhanced access to capital and operational resources. CERo has treated six patients in its Phase 1 CERTAIN-T trial with no dose-limiting toxicities observed at increased dose levels. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 1 | 1 |
| Three patients got a higher CER-1236 dose; no dose-limiting toxicities were observed. Results are preliminary. - Stock Titan | Three patients got a higher CER-1236 dose; no dose-limiting toxicities were observed. Results are preliminary. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| A 30-day rival-bid window accompanies SRX Global (NYSE: SRXH)'s planned CERo acquisition. - Stock Titan | A 30-day rival-bid window accompanies SRX Global (NYSE: SRXH)'s planned CERo acquisition. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| Fund holdings are intended for SRX shareholders, with timing still to come. - Stock Titan | Fund holdings are intended for SRX shareholders, with timing still to come. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| A planned shareholder dividend accompanies SRX Global’s (SRXH) commitment to launch active ETFs. - Stock Titan | A planned shareholder dividend accompanies SRX Global’s (SRXH) commitment to launch active ETFs. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| Srx Global Inc (SRXH-A) Stock Price and News - The Globe and Mail | Srx Global Inc (SRXH-A) Stock Price and News The Globe and Mail | View source ↗ | The Globe and Mail | Oct 2, 2026 | neutral | 0 | 0.6 |
| A robot's eyes hold cameras. SRX Global invested in Onconetix, which has an agreement to acquire Realbotix. - Stock Titan | A robot's eyes hold cameras. SRX Global invested in Onconetix, which has an agreement to acquire Realbotix. Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| SRX Global Inc (SRXH) (Q3 2026) Earnings Call Highlights: Strategic EMJX Acquisition and Record ... - Yahoo Finance | SRX Global Inc (SRXH) (Q3 2026) Earnings Call Highlights: Strategic EMJX Acquisition and Record ... Yahoo Finance | View source ↗ | Yahoo Finance | Aug 13, 2026 | neutral | 0 | 0.6 |
| SRXH Stock Falls Premarket Ahead Of Eric Jackson's Fireside Chat — Traders Brace For Buyback Clues And CEO Spotlight - TradingView | SRXH Stock Falls Premarket Ahead Of Eric Jackson's Fireside Chat — Traders Brace For Buyback Clues And CEO Spotlight TradingView | View source ↗ | TradingView | Jul 14, 2026 | neutral | 0 | 0.6 |
| SRXH Stock Falls Premarket Ahead Of Eric Jackson's Fireside Chat — Traders Brace For Buyback Clues And CEO Spotlight - Stocktwits | SRXH Stock Falls Premarket Ahead Of Eric Jackson's Fireside Chat — Traders Brace For Buyback Clues And CEO Spotlight Stocktwits | View source ↗ | Stocktwits | Jul 14, 2026 | neutral | 0 | 0.6 |
| SRX Global Reports Preliminary Net Asset Value of Approximately $3.07 Per Share and Over $55 Million in Cash and Short-Term Investments(1) - Yahoo Finance | SRX Global Reports Preliminary Net Asset Value of Approximately $3.07 Per Share and Over $55 Million in Cash and Short-Term Investments(1) Yahoo Finance | View source ↗ | Yahoo Finance | Jul 8, 2026 | neutral | 0 | 0.6 |
| SRXH Stock Crashed 20% Today – What’s Dampening Investors' Mood? - TradingView | SRXH Stock Crashed 20% Today – What’s Dampening Investors' Mood? TradingView | View source ↗ | TradingView | Jun 24, 2026 | neutral | 0 | 0.6 |
| SRXH Stock Crashed 20% Today – What’s Dampening Investors' Mood? - Yahoo Finance | SRXH Stock Crashed 20% Today – What’s Dampening Investors' Mood? Yahoo Finance | View source ↗ | Yahoo Finance | Jun 24, 2026 | neutral | 0 | 0.6 |
| SRX Global Approves 60-to-1 Stock Consolidation Effective July 6, 2026 | SRXH Stock News - Quiver Quantitative | SRX Global Approves 60-to-1 Stock Consolidation Effective July 6, 2026 | SRXH Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jun 24, 2026 | neutral | 0 | 0.6 |
| SRX Global Announces Share Consolidation - Yahoo Finance | SRX Global Announces Share Consolidation Yahoo Finance | View source ↗ | Yahoo Finance | Jun 24, 2026 | neutral | 0 | 0.6 |
| SRX backs a fentanyl countermeasure developer after early human data - Stock Titan | SRX backs a fentanyl countermeasure developer after early human data Stock Titan | View source ↗ | Stock Titan | Jun 23, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.